Hizal, MutluBilgin, BurakPaksoy, NailAçıkgöz, ÖzgürSezer, AhmetGürbüz, MustafaAk, NaziyeYücel, ŞebnemAyhan, MuratErol, CihanDemirkıran, AykutMandel, Nil MolinasShbair, AbdallahGökmen, İvoBaşoğlu, TuğbaPaydaş, SemraDemiray, Atike Gökçenİriağaç, YakupŞakalar, TeomanZeynelgil, EsraTatlı, Ali MuratBahçeci, AykutGüven, Deniz CanCaner, BurcuCan, AlperGülmez, AhmetKarakaş, YusufYalçın, BülentDemirkazık, AhmetBilici, AhmetAydıner, AdnanYumuk, Perran FuldenŞendur, Mehmet Ali Nahit2023-05-162023-05-162022-05-31https://hdl.handle.net/20.500.12645/37960Osimertinib, an irreversible third-generation EGFR-TKI, is the standard of care for second-line treatment of T790M-mutant advanced NSCLC patients whose disease progressed after first-line EGFR-TKI therapy. In this multicenter study, we aimed to determine the real-life efficacy and safety of Osimertinib in pretreated advanced NSCLC patients with T790M mutation.This retrospective trial included advanced T790M-mutant pretreated NSCLC patients who received Osimertinib from 24 different centers in Turkey. Primary endpoint was time-to-treatment discontinuation (TTD). Secondary endpoints were objective response rate (ORR), overall survival (OS), and safety.Of 163 patients, 68.7% had EGFR exon 19 deletion and 22.7% had exon 21 L858R mutation. Osimertinib was given as second-line treatment in 96 patients (58.9%) and third-line in 48 patients (29.4%). After median of 13-month follow-up, median TTD was 21.6 months with an 82.2% ORR. Estimated median OS was 32.1 months. Grade 3-4 adverse events were seen in 11.7% of the patients.Osimertinib is a highly effective option in second- or third-line treatment of NSCLC patients with T790M mutation, with a favorable safety profile.enEGFRNon-small cell lung cancerOsimertinibSecond lineT790M34331582